SCHEMBL1988650

SCHEMBL1988650

CC(C)(C)OC(=O)N1CCC[C@H](c2ccc(N)cc2)C1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 1/20 0.52
NR1H2 P55055 1/20 0.47
HPGDS O60760 1/20 0.47
ALDH1A1 P00352 2/20 0.46
MAPT P10636 2/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
JAK2 O60674 1/20 0.46
JAK1 P23458 1/20 0.46
NAMPT P43490 1/20 0.46
USP30 Q70CQ3 1/20 0.45
HSD11B1 P28845 1/20 0.45
PRMT5 O14744 1/20 0.44
NPC1 O15118 1/20 0.44
MAPK1 P28482 1/20 0.44
HTT P42858 1/20 0.44
RAB9A P51151 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
ALOX5AP P20292 1/20 0.44
FEN1 P39748 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1421908 1.00 PDE4B (0.52) PDE4BNR1H2HPGDSALDH1A1MAPT
SCHEMBL1422394 1.00 PDE4B (0.52) PDE4BNR1H2HPGDSALDH1A1MAPT
SCHEMBL12609696 0.93 PDE4B (0.58) PDE4BNR1H2HPGDSALDH1A1MAPT
SCHEMBL503247 0.93 PDE4B (0.58) PDE4BNR1H2HPGDSALDH1A1MAPT
SCHEMBL29537645 0.93 PDE4B (0.58) PDE4BNR1H2HPGDSALDH1A1MAPT
SCHEMBL20548030 0.92 PDE4B (0.46) PDE4BNR1H2HPGDSALDH1A1MAPT
SCHEMBL20548031 0.92 PDE4B (0.46) PDE4BNR1H2HPGDSALDH1A1MAPT
SCHEMBL25203147 0.91 NAMPT (0.56) PDE4BNR1H2ALDH1A1MAPTNAMPT
SCHEMBL21708067 0.91 NAMPT (0.50) PDE4BNR1H2ALDH1A1MAPTMEN1
SCHEMBL19074633 0.91 NAMPT (0.50) PDE4BNR1H2ALDH1A1MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4638433-A1 NAMPT MODULATORS Cytokinetics, Inc. (US) 2025-10-29 EP disclosed
US-20240279215-A1 NAMPT MODULATORS CYTOKINETICS, INCORPORATED 2024-08-22 US disclosed
WO-2024137981-A1 NAMPT MODULATORS CYTOKINETICS, INCORPORATED (US) 2024-06-27 WO disclosed
US-11697636-B2 Substituted benzamides HOFFMANN-LA ROCHE INC. (US) 2023-07-11 US disclosed
EP-3694836-B1 PROCESS FOR PREPARING INTERMEDIATE OF ANTI-TUMOR DRUG NIRAPARIB AND INTERMEDIATE THEREOF ZAI LAB SHANGHAI CO LTD (CN) 2022-06-15 EP disclosed
EP-3187490-B1 SUBSTITUTED BENZAMIDE DERIVATIVES HOFFMANN LA ROCHE (CH) 2022-04-06 EP disclosed
US-11161834-B2 Methods of manufacturing of niraparib TESARO, INC. (US) 2021-11-02 US disclosed
US-20210061760-A1 SUBSTITUTED BENZAMIDES HOFFMANN LA ROCHE (US) 2021-03-04 US disclosed
US-20200055837-A1 METHODS OF MANUFACTURING OF NIRAPARIB TESARO, INC. 2020-02-20 US disclosed
US-20200048194-A1 SUBSTITUTED BENZAMIDES F. HOFFMANN-LA ROCHE AG (CH) 2020-02-13 US disclosed
EP-3187490-A1 SUBSTITUTED BENZAMIDE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2017-07-05 EP disclosed
US-9452980-B2 Substituted benzamides HOFFMANN-LA ROCHE INC. (US) 2016-09-27 US disclosed
US-20160264596-A1 SUBSTITUTED BENZAMIDES HOFFMANN-LA ROCHE INC. 2016-09-15 US disclosed
US-20110152245-A1 SUBSTITUTED BENZAMIDES F. HOFFMANN-LA ROCHE AG (CH) 2011-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200055837-A1 METHODS OF MANUFACTURING OF NIRAPARIB PARP2, PARP1, PARP3 PDE4B 1355/4885NR1H2 4776/4885HPGDS 695/4885
US-20160264596-A1 SUBSTITUTED BENZAMIDES TAAR1, TAAR5, NPY1R PDE4B 1008/4885NR1H2 284/4885HPGDS 4601/4885
US-20240279215-A1 NAMPT MODULATORS NAMPT, SIRT1, NNT PDE4B 162/4885NR1H2 326/4885HPGDS 2321/4885
US-20210061760-A1 SUBSTITUTED BENZAMIDES TAAR1, TAAR5, NPY1R PDE4B 1008/4885NR1H2 284/4885HPGDS 4601/4885
US-20110152245-A1 SUBSTITUTED BENZAMIDES TAAR1, TAAR5, NPY1R PDE4B 1008/4885NR1H2 284/4885HPGDS 4601/4885
US-11161834-B2 Methods of manufacturing of niraparib PARP2, PARP1, PARP3 PDE4B 1355/4885NR1H2 4776/4885HPGDS 695/4885
US-20200048194-A1 SUBSTITUTED BENZAMIDES TAAR1, TAAR5, NPY1R PDE4B 1008/4885NR1H2 284/4885HPGDS 4601/4885
US-11697636-B2 Substituted benzamides TAAR1, TAAR5, NPY1R PDE4B 1008/4885NR1H2 284/4885HPGDS 4601/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.